Cargando…

A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis

The aim of this study was to evaluate cenicriviroc (CVC), a dual antagonist of C—C chemokine receptor types 2 and 5, for treatment of nonalcoholic steatohepatitis (NASH) with liver fibrosis (LF). A randomized, double‐blind, multinational phase 2b study enrolled subjects with NASH, a nonalcoholic fat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Friedman, Scott L., Ratziu, Vlad, Harrison, Stephen A., Abdelmalek, Manal F., Aithal, Guruprasad P., Caballeria, Juan, Francque, Sven, Farrell, Geoffrey, Kowdley, Kris V., Craxi, Antonio, Simon, Krzysztof, Fischer, Laurent, Melchor‐Khan, Liza, Vest, Jeffrey, Wiens, Brian L., Vig, Pamela, Seyedkazemi, Star, Goodman, Zachary, Wong, Vincent Wai‐Sun, Loomba, Rohit, Tacke, Frank, Sanyal, Arun, Lefebvre, Eric
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947654/ https://www.ncbi.nlm.nih.gov/pubmed/28833331 http://dx.doi.org/10.1002/hep.29477

Ejemplares similares

Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study
por: Anstee, Quentin M., et al.
Publicado: (2023)

Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet‐induced mouse model of nonalcoholic steatohepatitis
por: Kruger, Annie J., et al.
Publicado: (2018)

APOBEC3G/3A Expression in Human Immunodeficiency Virus Type 1-Infected Individuals Following Initiation of Antiretroviral Therapy Containing Cenicriviroc or Efavirenz
por: Covino, Daniela A., et al.
Publicado: (2018)

Efficacy of evogliptin and cenicriviroc against nonalcoholic steatohepatitis in mice: a comparative study
por: Wang, Zheng, et al.
Publicado: (2019)

Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study
por: Eksteen, Bertus, et al.
Publicado: (2020)

Evaluating the Therapeutic Potential of Cenicriviroc in the Treatment of Nonalcoholic Steatohepatitis with Fibrosis: A Brief Report on Emerging Data
por: Diaz Soto, Maria Paula, et al.
Publicado: (2020)

Differential impact of the dual CCR2/CCR5 inhibitor cenicriviroc on migration of monocyte and lymphocyte subsets in acute liver injury
por: Puengel, Tobias, et al.
Publicado: (2017)

Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science
por: Siddiqui, Mohammad Shadab, et al.
Publicado: (2018)

Role of cenicriviroc in the management of nonalcoholic fatty liver disease
por: Neokosmidis, Georgios, et al.
Publicado: (2018)

Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19
por: Files, Daniel Clark, et al.
Publicado: (2022)

Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis
por: Sanyal, Arun J., et al.
Publicado: (2023)

The scaffold-dependent function of RIPK1 in experimental non-alcoholic steatohepatitis
por: Pistorio, Valeria, et al.
Publicado: (2022)

Cenicriviroc blocks HIV entry but does not lead to redistribution of HIV into extracellular space like maraviroc
por: Kramer, Victor, et al.
Publicado: (2014)

The Nimble Stage 1 Study Validates Diagnostic Circulating Biomarkers for Nonalcoholic Steatohepatitis
por: Sanyal, Arun, et al.
Publicado: (2023)

TERN-101, a farnesoid X receptor agonist, demonstrated similar safety and efficacy in non-alcoholic steatohepatitis patients with coronavirus disease of 2019 (COVID-19) exposure compared to those with no COVID-19 exposure in phase 2a LIFT study
por: Lawitz, Eric, et al.
Publicado: (2022)

Pharmacokinetics, Safety, and CCR2/CCR5 Antagonist Activity of Cenicriviroc in Participants With Mild or Moderate Hepatic Impairment
por: Lefebvre, E, et al.
Publicado: (2016)

Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity
por: Newsome, Philip, et al.
Publicado: (2019)

Immunological Mechanisms in the Pathophysiology of Non-Alcoholic Steatohepatitis
por: Vonghia, Luisa, et al.
Publicado: (2013)

Validation of the accuracy of the FAST(™) score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms
por: Woreta, Tinsay A., et al.
Publicado: (2022)

Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis
por: Lefebvre, Eric, et al.
Publicado: (2016)

A randomised Phase IIa trial of amine oxidase copper-containing 3 (AOC3) inhibitor BI 1467335 in adults with non-alcoholic steatohepatitis
por: Newsome, Philip N., et al.
Publicado: (2023)

The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro
por: Okamoto, Mika, et al.
Publicado: (2020)

Therapeutic approaches for non-alcoholic steatohepatitis
por: Van Gaal, Luc F., et al.
Publicado: (2021)

Sofosbuvir, a Significant Paradigm Change in HCV Treatment
por: McQuaid, Thomas, et al.
Publicado: (2015)

Cenicriviroc for the treatment of COVID-19: first interim results of a randomised, placebo-controlled, investigator-initiated, double-blind phase II trial
por: Kurth, Florian, et al.
Publicado: (2023)

Clinical practice gaps and challenges in non‐alcoholic steatohepatitis care: An international physician needs assessment
por: Lazure, Patrice, et al.
Publicado: (2022)

Hepatic Molecular Signatures Highlight the Sexual Dimorphism of Nonalcoholic Steatohepatitis (NASH)
por: Vandel, Jimmy, et al.
Publicado: (2020)

MRI‐Proton Density Fat Fraction Treatment Response Criteria in Nonalcoholic Steatohepatitis
por: Loomba, Rohit
Publicado: (2021)

Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient‐Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis
por: Younossi, Zobair M., et al.
Publicado: (2021)

Emerging advances in the pharmacologic treatment of nonalcoholic steatohepatitis and related cirrhosis
por: Sinakos, Emmanouil, et al.
Publicado: (2022)

From the Editor's Desk…
por: Burra, Patrizia, et al.
Publicado: (2020)

From the Editor's Desk…
por: Burra, Patrizia, et al.
Publicado: (2020)

From the Editor's Desk...
por: Burra, Patrizia, et al.
Publicado: (2020)

From the Editor’s Desk…
por: Burra, Patrizia, et al.
Publicado: (2021)

From the Editor’s Desk…
por: Burra, Patrizia, et al.
Publicado: (2021)

From the Editor’s Desk…
por: Burra, Patrizia, et al.
Publicado: (2022)

From the Editor’s Desk…
por: Burra, Patrizia, et al.
Publicado: (2023)

Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges
por: Dufour, Jean-François, et al.
Publicado: (2020)

Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates
por: Visseaux, Benoit, et al.
Publicado: (2015)

Inflammatory Mechanisms Underlying Nonalcoholic Steatohepatitis and the Transition to Hepatocellular Carcinoma
por: Peiseler, Moritz, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_midbikvfpfq3ghiheubfedu2gd